

Barcelona, Spain,
July 22, 2020

Almirall calls for collaborative innovation to advance new treatments for skin diseases

- **[AlmirallShare](#) launches its fifth call for proposals, aiming to establish partnerships to find new assets—new chemical entities, biologics and other advanced therapies—for the treatment of dermatological conditions**
- **Scientists can participate until October 31, 2020**
- **AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 350 proposals since its launch in 2017**

AlmirallShare, the open innovation platform of **Almirall, S.A. (ALM)**, launches its fifth call, aiming to establish collaborations in dermatological research and identify new treatments for skin health. The call seeks partnering opportunities for new assets—new chemical entities, biologics and other advanced therapies—in order to maximize their value as innovative therapies. With this call to the scientific community, Almirall opts once again to unite the science and creativity of experts from around the world with the company's knowledge and expertise.

Assets submitted for consideration must be in late research or preclinical development stages, address a specific pathway, and demonstrate a therapeutic potential for treating dermatological conditions

AlmirallShare is responsible for approximately 50% of the private-public collaborations driven by Almirall. Since its launch in 2017, more than 900 scientists have shown interest in participating and more than 350 proposals have been received. To date, six collaborations have been established, based on new therapies (IDIBAPS, University of Turin), new targets (Dublin City University, University of Namur), and new preclinical models (University College Dublin, University of Sheffield). Additionally, three new collaborative projects are expected to start very soon.

With this fifth call, AlmirallShare reinforces its commitment to collaborative and shared innovation in R&D by offering a partnership opportunity and asset characterisation conducted by Almirall in a pre-agreed panel of relevant cellular assays and *in vivo* models of dermatological diseases. In all cases, applicants will retain ownership of their intellectual property.

Scientists affiliated with start-ups, biotechs, universities, research centres, and pharmaceutical companies from anywhere in the world may submit their proposals on sharedinnovation.almirall.com from July 20, 2020 to October 31, 2020. Terms and conditions can be found on the website.

“AlmirallShare calls were very well received by the scientific community. This encourages us to continue promoting new partnership projects in R&D to develop innovative solutions in medical dermatology. After having started what looks to be very promising collaborative projects since 2017, AlmirallShare has become a

key tool for successful strategic partnerships that will translate into advances in treatments for dermatological conditions,” said **Maribel Crespo, AlmirallShare leader.**

AlmirallShare. Bringing Science and creativity together

AlmirallShare was launched in 2017 as an open innovation R&D platform designed to facilitate the establishment of collaborations in dermatological research and find innovative solutions in medical dermatology. By bringing together the science and creativity of experts from around the world and Almirall’s own expertise, the AlmirallShare initiative accelerates the generation of new treatments for skin conditions. The main objectives of this project are to open up the innovation process to foster collaboration projects with partners worldwide, to share opportunities and knowledge with the scientific community in a structured, agile, and transparent manner, as well as to identify innovative solutions to dermatological needs and challenges. AlmirallShare aims to reach out to scientists at universities, public or private research institutions, hospitals, start-ups, and biotechnology and pharmaceutical companies to address challenges such as the identification of therapeutic targets and experimental disease models, the development of new therapeutic treatments as well as novel technologies in dermatology. Almirall converts these challenges into Calls for Proposals (CFPs) which are then published on sharedinnovation.almirall.com

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

Media contact

TINKLE

Pilar Colomer

pcolomer@tinkle.es

Tel.: (+34) 607 55 08 61

Almirall

Corporate Communications contact:

Noel Ortiz

noel.ortiz@almirall.com

Phone.: (+34) 932 913 000

Investors Relations contact:

Pablo Divasson del Fraile

pablo.divasson@almirall.com

Phone: (+34) 932 913 087

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate Communication [click here](#)

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy [here](#). At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver’s license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.